Purpose Aggregation aspects of therapeutic monoclonal antibodies (mAbs) are of common
concern to the pharmaceutical industry. Low pH treatment is applied during affinity …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Monomer unfolding and thermally accelerated aggregation kinetics to produce soluble
oligomers or insoluble macroscopic aggregates were characterized as a function of pH for …

Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine
the specificity of therapeutic antibodies with the pharmacological potency of chemical …

Purpose To identify the aggregation mechanism and the stability characteristics of three
different monoclonal antibodies under acidic conditions. Methods The aggregation kinetics …

Changes in protein–protein interactions, protein unfolding, and nonnative aggregation were
assessed for a series of human IgG1 antibodies as a function of pH and solution ionic …

Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy,
combining the antibody's exquisite specificity for the target antigen-expressing cancer cell …

The prevention of aggregation in therapeutic antibodies is of great importance to the
biopharmaceutical industry. In our investigation, acid-induced aggregation of monoclonal …

Understanding antibody aggregation is of great significance for the pharmaceutical industry.
We studied the aggregation of five different therapeutic monoclonal antibodies (mAbs) with …

Monoclonal antibodies are the fastest growing class of therapeutics. However, aggregation
limits their shelf life and can lead to adverse immune responses. Assessment and …